hepatic glutathione content in liver diseases and hepatotoxicity Glutathione-mediated biotransformation in the liver
Description
These factors along with the restricted experience in the use of the most medicines in childhood and elderly, could explain at an extent the inter-individual variability in drug efficacy and toxicity outcomes, and underscore the necessity of designing the treatment protocols, accordingly
Similarly, NSCLC has been described in several studies to be vulnerable to the induction of ferroptosis
There was nothing I could do
Safety begins with proper screening, including evaluation of kidney function, glucose-6-phosphate dehydrogenase status, and a review of medications and medical history
